Max Healthcare Institute (543220) Q2 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 24/25 earnings summary
16 Jan, 2026Executive summary
Achieved strong growth in Q2 and H1 FY25, driven by acquisitions, integration of new hospitals, and launch of MSSH Dwarka, with network revenue reaching INR 2,228 crores, up 22% year-on-year and 10% quarter-on-quarter.
Acquired a controlling stake in Jaypee Healthcare Ltd, adding major hospitals in Noida and Chitta, and commenced operations at a new 303-bed greenfield hospital in Dwarka.
Board approved unaudited standalone and consolidated financial results for Q2 and H1 FY25, with unmodified review reports.
International patient revenue grew 12% year-on-year and quarter-on-quarter to INR 178 crores, despite lower footfall from Bangladesh and Yemen.
Digital revenue contributed INR 524 crores (~23% of total), with website traffic up 37% year-on-year.
Financial highlights
Network operating EBITDA (excluding extraordinary items) was INR 591 crores, up 19% year-on-year and 17% quarter-on-quarter, with a margin of 28.2%.
Profit after tax (excluding extraordinary items) stood at INR 383 crores, up 13% year-on-year; consolidated PAT for Q2 FY25 was INR 349 crores.
Free cash flow from operations was INR 464 crores in Q2, with INR 217 crores deployed towards expansion and upgrades; net cash position improved to INR 313 crores at September 2024.
Consolidated revenue from operations for Q2 FY25 was ₹170,746 lakhs, up from ₹136,316 lakhs in Q2 FY24.
EBITDA per bed (annualized) was INR 75.5 lakhs in Q2 FY25.
Outlook and guidance
Operational bed capacity targeted to increase from 376 to 430 by March and over 480 by December 2025, with further expansion in Jaypee Hospital and MSSH Dwarka.
Plans to set up a 250+ bedded super specialty hospital in Zirakpur, Punjab, under a long-term lease.
Focus on brownfield, greenfield, and asset-light expansion, targeting ~2x bed capacity in 4-5 years.
ROCE threshold of 20-25% within 4-5 years post-acquisition for new units.
Latest events from Max Healthcare Institute
- Q3 FY26 delivered strong growth, with expansion and regulatory changes shaping future performance.543220
Q3 25/266 Feb 2026 - 18% revenue growth, high occupancy, and major expansion with a new hospital in Zirakpur.543220
Q1 24/252 Feb 2026 - Q3 FY25 revenue up 34% YoY, EBITDA up 32%, with major expansion and strong cash flow.543220
Q3 24/259 Jan 2026 - Revenue up 27% YoY, EBITDA up 23%, and PAT up 17% amid robust expansion and digital growth.543220
Q1 25/2623 Nov 2025 - FY25 revenue up 26% with strong EBITDA growth, expansion, and a recommended dividend.543220
Q4 24/2518 Nov 2025 - Q2 FY26 saw strong growth, expansion, and digital gains, supported by key divestments and a merger.543220
Q2 25/2617 Nov 2025